Neuralink announced on May 7, 2026 that its next-generation surgical robot can place electrode threads into virtually any region of the human brain — a capability that moves the company's ambitions well past motor-function restoration and into the territory of treating Parkinson's disease, refractory epilepsy, and treatment-resistant depression.